What's Going On With Gene Therapy Company Bluebird Bio Stock Today?
Bluebird Bio, Inc. (NASDAQ:BLUE), on Friday, entered into a definitive agreement to be acquired by global investment firms ...
Title: bluebird bio Announces Positive Phase 1/2 Clinical Trial Data for Gene Therapy
In recent financial reports submitted to the Securities and Exchange Committee (SEC) in an 8-K filing, bluebird bio, Inc. (NASDAQ: BLUE), a leading biotech company, has provided an update on their ...
FiercePharma1d
Once valued at $10B, bluebird bio sold to private equity firms for $29M
There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...
Once a darling of biotech, bluebird sells for less than $30M upfront
Somerville gene therapy company bluebird bio, once among the highest-profile biotechs in the Boston area, has agreed to be ...
Struggling Somerville biotech Bluebird Bio to be sold for less than $30 million
Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...